SuperGen Appoints David Bearss, Ph.D., Chief Scientific Officer
November 17 2008 - 8:00AM
PR Newswire (US)
DUBLIN, Calif., Nov. 17 /PRNewswire-FirstCall/ -- SuperGen Inc.
(NASDAQ:SUPG) today announced the promotion of David Bearss, Ph.D.,
to Chief Scientific Officer. Dr. Bearss will continue to lead
SuperGen's discovery and pre-clinical development strategies and
execution as SuperGen continues to accelerate the discovery and
advancement into the clinic of novel drug candidates. His
responsibilities will include the oversight of target selection,
product creation and early stage development. "As we move deeper
into the frontiers of novel pharmaceutical space to address unmet
medical needs, and expand our proprietary portfolio, Dave's
scientific vision and leadership, and his extensive research and
development experience, will continue to enable our Company to
rapidly and efficiently identify, create and advance new drug
candidates," said James S. Manuso, Ph.D., Chairman, President and
CEO of SuperGen. Dr. Bearss joined SuperGen as a result of the
Company's acquisition of Montigen Pharmaceuticals, Inc. in 2006. He
cofounded and served as Montigen's scientific leader. Dr. Bearss is
at the core of SuperGen's scientific innovation, and has enabled
the discovery of the kinase inhibitors, MP-470 and SGI-1776.
Emerging areas of his interest include the inhibition of protein-
protein interactions, second-generation epigenetic inhibitors, and
potential therapeutic applications of SuperGen's CLIMB(TM)
discovery platform outside of cancer. Dr. Bearss is a recognized
expert in targeted small-molecule drug development and the use of
genetic model systems for drug discovery and evaluation. He
pioneered the development of new targeted therapeutics and has been
recognized for his work in validation and drug discovery projects
with targets including telomerase, nuclear hormone receptors and
aurora kinases. In 1999, as a fellow at the Cancer Therapy and
Research Center (CTRC) in San Antonio, Texas, Dr. Bearss
collaborated with Dr. Daniel Von Hoff, a recognized leader in drug
development who has conducted more than 200 clinical trials with
new antineoplastic and biologic agents. Dr. Bearss subsequently
joined the faculty of the University of Arizona as an Assistant
Professor in the Department of Molecular and Cellular Biology and a
member of the Arizona Cancer Center where he invented and developed
several novel, targeted chemical entities. Dr. Bearss holds a B.S.
degree from Brigham Young University and a Ph.D. in Cell and
Molecular Biology from the University of Texas Health Science
Center at San Antonio. He has published more than thirty
manuscripts and book chapters and has won several awards for his
scientific achievements. Dr. Bearss has served as a pharmaceutical
industry consultant, with respect to the development of cancer
therapeutics, for several biotechnology companies prior to founding
Montigen Pharmaceuticals. About SuperGen Based in Dublin, Calif.,
SuperGen, Inc. is a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies. SuperGen is
developing a number of therapeutic anticancer products focused on
kinase and cell signaling inhibitors and DNA methyltransferase
inhibitors. For more information about SuperGen, please visit
http://www.supergen.com/. This press release contains
"forward-looking" statements within the meaning of Section 21A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and is subject to the
safe harbor created thereby. The actual results could differ
materially from those projected in the forward-looking statements
as a result of a number of risks and uncertainties. These
forward-looking statements include statements regarding the ability
of our products to enter clinical trials and the potential
validation of our discovery process to produce new compounds.
SuperGen's products may not enter clinical trials and even if these
products do enter clinical testing there is no assurance that these
tests will be successful. Additionally, the early successes in
preclinical work may not be a validation of our discovery process
and past success may not predict future success. Other factors that
could cause actual results to differ materially from expectations
include, but are not limited to, the risk factors detailed in the
Company's filings with the Securities and Exchange Commission
including reports on its most recently filed Form 10-K and Form
10-Q. These forward- looking statements are made only as of the
date hereof, and we disclaim any obligation to update or revise the
information contained in any such forward- looking statements,
whether as a result of new information, future events or otherwise.
Contacts: SuperGen Timothy L. Enns S.V.P., Corporate Communications
& Business Development (925) 560-2810 Dorland Global Public
Relations Michael Beckerich (Media) Tel: (212) 677-7632 DATASOURCE:
SuperGen Inc. CONTACT: Timothy L. Enns, S.V.P., Corporate
Communications & Business Development of SuperGen,
+1-925-560-2810, ; Michael Beckerich (Media), Dorland Global Public
Relations, +1-212-677-7632,
Copyright
Supergen, Inc. (MM) (NASDAQ:SUPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Supergen, Inc. (MM) (NASDAQ:SUPG)
Historical Stock Chart
From Sep 2023 to Sep 2024